What 8 Analyst Ratings Have To Say About Revance Therapeutics
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter:
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Revance Therapeutics’s Earnings: A Preview
Revance Therapeutics (NASDAQ:RVNC) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Revance Therapeutics will report an earnings per share (EPS) of $-0.89.
What 7 Analyst Ratings Have To Say About Revance Therapeutics
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter:
AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.
‘Right Now, You’ve Still Got To Avoid The Stock,’ Jim Cramer Says About This Aerospace Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock.
What 6 Analyst Ratings Have To Say About Revance Therapeutics
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter:
Goldman Sachs Initiates Coverage On Revance Therapeutics with Buy Rating, Announces Price Target of $33
Goldman Sachs analyst Chris Shibutani initiates coverage on Revance Therapeutics (NASDAQ:RVNC) with a Buy rating and announces Price Target of $33.
Revance To Present Data From Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY At MDS Congress Sept. 16
- Oral poster showcasing positive results from Revance's Phase 2 JUNIPER clinical trial, which demonstrated long-term efficacy and safety with DAXXIFY™ for the treatment of upper limb spasticity (ULS)